ANALYSIS: Unravelling Japan’s Biosimilar Opportunities
This article was originally published in PharmAsia News
Executive Summary
MP Advisors sees a cumulative biosimilars opportunity of around JPY400 billion ($3.31 billion) in Japan over the next five years as some big-selling biologics come off local patent. But the next few years will provide further clarity on the value of different strategies for complex monoclonal antibody (mAb) biosimilar penetration in the country.
You may also be interested in...
Japan Rebound For Amgen With Daiichi Biosimilars Deal
A few weeks after its R&D alliance in Japan with Takeda was scaled back, Amgen has found a new partner in the country, this time for the commercialization of a broad portfolio of biosimilars.
Japan Rebound For Amgen With Daiichi Biosimilars Deal
A few weeks after its R&D alliance in Japan with Takeda was scaled back, Amgen has found a new partner in the country, this time for the commercialization of a broad portfolio of biosimilars.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.